Bimeda UK launches first generic intrauterine cefapirin suspension for dairy cattle post-partum

Bimeda UK introduces BIMACURE, a targeted intrauterine cefapirin suspension to combat post-partum uterine disease in dairy cows, marking its expansion into large-animal therapeutics.

Bimeda UK has added BIMACURE, an intrauterine cefapirin suspension for cattle, to its large-animal portfolio, positioning the product as a targeted option for post-partum uterine disease. According to the company and coverage in VetClick, the medicine is designed for subacute and chronic endometritis in cows and comes as 500 mg cefapirin per syringe, with the manufacturer highlighting syringeability and a syringe-catheter connection intended to reduce disconnections during administration.

The product is supplied in packs of ten, each including a syringe, administration catheter and gloves for on-farm use. Bimeda says it is aimed at cows at least 14 days after calving, while the package leaflet published by the Veterinary Medicines Directorate gives the indication as subacute and chronic endometritis in cows from 14 days post-parturition, caused by bacteria susceptible to cefapirin. Bimeda’s product information also describes Bimacure as a prescription-only medicine and states that it is the first generic intrauterine cefapirin suspension marketed in Ireland.

Endometritis remains a common fertility problem in dairy herds, with VetClick citing an incidence of 10% to 15% after calving and noting links to poorer fertility and lower milk output. The company’s technical and commercial veterinarian, Rachel Mallet, said the launch adds to Bimeda’s expanding livestock range and supports management of the post-partum period.

According to the product information, withdrawal periods are one day for meat and offal and zero hours for milk.

Image Source: Bimeda